Previous close | 7.04 |
Open | 7.00 |
Bid | 7.01 x 100 |
Ask | 7.10 x 100 |
Day's range | 6.97 - 7.08 |
52-week range | 5.53 - 12.45 |
Volume | |
Avg. volume | 509,135 |
Market cap | 831.59M |
Beta (5Y monthly) | 1.39 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.79 |
Earnings date | 02 May 2024 - 06 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 10.40 |
Medtech commercial teams can now solve frontline sales challenges with exceptional data and streamlined workflowsFRAMINGHAM, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced the launch of Carevoyance, an innovative sales enablement solution tailored for medtech organizations. Acquired by Definitive Healthcare in January 2024, Carevoyance tackles frontline sales challenges head-on. It’s a powerf
Partnership offers solution to streamline engagement between pharmaceutical companies and KOLs to help increase the value of the clinical collaborations and conversationsFRAMINGHAM, Mass. and LONDON, March 22, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH) and VML Health announced a first-of-its-kind partnership that gives clients the ability to manage their entire key opinion leader (KOL) identification and engagement operation from an integrated solution. This partnership provides
FRAMINGHAM, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that it has been named one of the Boston Business Journal’s Middle Market Leaders for 2024, a ranking of the 50 highest growth companies in Massachusetts. This marks the second year in a row that Definitive Healthcare has won this award. The Boston Business Journal selects the Middle Market Leaders using a weighted index score based o